Showing 121 - 140 results of 49,647 for search '(((( 50 we decrease ) OR ( 2 c decrease ))) OR ( 50 ((ms decrease) OR (a decrease)) ))', query time: 0.91s Refine Results
  1. 121
  2. 122
  3. 123

    Integration of Segmented Ion Fractionation and Differential Ion Mobility on a Q‑Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer by Sibylle Pfammatter (3226209)

    Published 2021
    “…FAIMS was also combined with segmented ion fractionation where 100 <i>m</i>/<i>z</i> windows were obtained in turn to further increase the depth of proteome analysis by reducing the proportion of chimeric MS/MS spectra from 50 to 27%. We also demonstrate the application of FAIMS to improve quantitative measurements when using isobaric peptide labeling. …”
  4. 124

    Integration of Segmented Ion Fractionation and Differential Ion Mobility on a Q‑Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer by Sibylle Pfammatter (3226209)

    Published 2021
    “…FAIMS was also combined with segmented ion fractionation where 100 <i>m</i>/<i>z</i> windows were obtained in turn to further increase the depth of proteome analysis by reducing the proportion of chimeric MS/MS spectra from 50 to 27%. We also demonstrate the application of FAIMS to improve quantitative measurements when using isobaric peptide labeling. …”
  5. 125

    Integration of Segmented Ion Fractionation and Differential Ion Mobility on a Q‑Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer by Sibylle Pfammatter (3226209)

    Published 2021
    “…FAIMS was also combined with segmented ion fractionation where 100 <i>m</i>/<i>z</i> windows were obtained in turn to further increase the depth of proteome analysis by reducing the proportion of chimeric MS/MS spectra from 50 to 27%. We also demonstrate the application of FAIMS to improve quantitative measurements when using isobaric peptide labeling. …”
  6. 126

    Integration of Segmented Ion Fractionation and Differential Ion Mobility on a Q‑Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer by Sibylle Pfammatter (3226209)

    Published 2021
    “…FAIMS was also combined with segmented ion fractionation where 100 <i>m</i>/<i>z</i> windows were obtained in turn to further increase the depth of proteome analysis by reducing the proportion of chimeric MS/MS spectra from 50 to 27%. We also demonstrate the application of FAIMS to improve quantitative measurements when using isobaric peptide labeling. …”
  7. 127

    <i>Kdm6a</i> conditional KO mice have decreased repopulating potential in serial competitive transplantation assays. by Ling Tian (107492)

    Published 2021
    “…Whole BM cells were harvested from all cohorts of young <i>Kdm6a</i> conditional KO mice (CD45.2) and mixed with WT competitor marrow (CD45.1 x CD45.2) in a 1:1 ratio, which was then transplanted into lethally-irradiated primary recipient mice (CD45.1). …”
  8. 128

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
  9. 129

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135

    Table_1_Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts.DOCX by Hong Zhang (25820)

    Published 2020
    “…However, EMPA did specifically decrease cardiac lactate labeling in the <sup>13</sup>C glucose perfusions (<sup>13</sup>C labeling of lactate: 58 ± 2% vs. 50 ± 3%, for vehicle and EMPA, respectively; P = 0.02), without changes in other glucose metabolic pathways. …”
  16. 136
  17. 137
  18. 138
  19. 139
  20. 140